IGM Biosciences Terminates Material Definitive Agreement
| Field | Detail |
|---|---|
| Company | Igm Biosciences, Inc. |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, 8-k
TL;DR
IGM Biosciences just terminated a big deal. Details TBD.
AI Summary
IGM Biosciences, Inc. announced on May 5, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K report on May 8, 2025, detailing the event. No specific details regarding the agreement or the counterparty were provided in the filing excerpt.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's strategic direction, financial performance, and ongoing business relationships.
Risk Assessment
Risk Level: medium — Termination of a material agreement can signal underlying issues or strategic shifts that may pose risks to the company's future operations and financial health.
Key Numbers
- 001-39045 — Commission File Number (Identifies the company's SEC filings)
- 77-0349194 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- IGM Biosciences, Inc. (company) — Registrant
- May 5, 2025 (date) — Date of earliest event reported
- May 8, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 325 E. Middlefield Road, Mountain View, California 94043 (address) — Principal Executive Offices
FAQ
What was the material definitive agreement that was terminated?
The provided excerpt does not specify the details of the material definitive agreement that was terminated.
Who was the other party to the terminated agreement?
The filing excerpt does not disclose the identity of the other party involved in the terminated agreement.
What is the effective date of the termination?
The earliest event reported, which includes the termination, occurred on May 5, 2025.
Why was the agreement terminated?
The reasons for the termination of the material definitive agreement are not detailed in the provided filing excerpt.
What are the implications of this termination for IGM Biosciences?
The filing excerpt does not elaborate on the specific implications or consequences of the agreement's termination for IGM Biosciences.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding IGM Biosciences, Inc..